ABOUT US

A global leader in innovative genomic
technology and diagnostic tests.


What’s new at Agendia?

Get the latest updates on our company and products, as well as new developments in genomic science.

News

In the News

Who We Are

Our purpose, our story our vision. Hear how Agendia fits into the evolving landscape of technology and cancer care.

Two women reading about genomic breast cancer results

Latest Data

Agendia Presents New Data Demonstrating MammaPrintโ€™s Clinical Utility in Treatment Decisions for Ultra-Low Risk Breast Cancer Patients [โ€ฆ]

I Am Here breast cancer illustration

Patient News

Agendia and artist Andrea Caceres go โ€œbeyond the mammogramโ€ in a portrait series illustrating people touched by breast cancer.

News

Media Releases

Agendia Achieves Historic Milestone of Enrolling 10,000 Patients in FLEX, the Largest-Ever Prospective, Real-World-Evidence Trial for Patients With Early Stage Breast Cancer

May 25th, 2022|

Company to present multiple recent Registry sub-studies driving cancer care innovation at ASCO 2022 IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS โ€“ May 25, 2022 โ€“ Agendia, Inc., a commercial-stage company focused on improving outcomes for Read More

Agendia Demonstrates Accessibility and Affordability of MammaPrint and BluePrint in Europe at ESMO Breast Cancer 2022

May 3rd, 2022|

Next-generation sequencing version of MammaPrint and BluePrint enables decentralized testing in CE-mark jurisdictions like Germany Analysis for Belgian Health Care Package shows MammaPrint yields cost-savingsย for breast cancer care systemically IRVINE, Calif. & AMSTERDAM--(BUSINESS WIRE)--Agendia, Inc., Read More